Literature DB >> 31128121

Galanin (1-15)-fluoxetine interaction in the novel object recognition test. Involvement of 5-HT1A receptors in the prefrontal cortex of the rats.

Antonio Flores-Burgess1, Carmelo Millón1, Belen Gago1, Laura García-Durán1, Noelia Cantero-García1, Rafael Coveñas2, José Angel Narváez1, Kjell Fuxe3, Luis Santín4, Zaida Díaz-Cabiale5.   

Abstract

Galanin (1-15) [GAL(1-15)] participates in mood regulation and depression. GAL(1-15) is also able to enhance the antidepressant effects induced by Fluoxetine (FLX) in the forced swimming test through interaction between GALR1-GALR2 and 5-HT1A receptors that induced changes in the binding characteristics and mRNA of the 5-HT1AR in the hippocampus. Since the medial prefrontal cortex (mPFC) is a core region for the interaction between emotional processing and cognition with a high density of 5-HT1AR and GALR1 and GALR2, we have analyzed the binding characteristics and mRNA levels of 5-HT1AR in the mPFC after GAL(1-15)-FLX administration in the rats. GAL(1-15) increased the Kd and the Bmax of the 5HT1AR agonist binding in the mPFC as well as the mRNA levels of 5-HT1AR in mPFC. Moreover, GAL(1-15) reversed the effects of memory impairment induced by FLX(10 mg/kg) in the Novel Object Recognition task. GALR2 was involved in these effects, since the specific GALR2 antagonist M871 blocked GAL(1-15) mediated actions at behavioral level. On the contrary GAL(1-15) did not reverse the effect of FLX in the Object Location Memory task. In conclusion, our results describe an interactions between GAL(1-15) and FLX in the mPFC involving interactions at the 5-HT1AR receptor level in the plasma membrane with changes at the transcriptional level with implications also at functional level. The GALR1-GALR2-5-HT1A heteroreceptor could be postulated to be used to reverse some of the adverse effects of FLX on memory processes.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31128121     DOI: 10.1016/j.neuropharm.2019.05.023

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  Cell-type specific knockout of peptidylglycine α-amidating monooxygenase reveals specific behavioral roles in excitatory forebrain neurons and cardiomyocytes.

Authors:  Kathryn G Powers; Xin-Ming Ma; Betty A Eipper; Richard E Mains
Journal:  Genes Brain Behav       Date:  2020-09-24       Impact factor: 3.449

Review 2.  Novel Pharmacological Approaches to the Treatment of Depression.

Authors:  Elias Elias; Ariel Y Zhang; Melissa T Manners
Journal:  Life (Basel)       Date:  2022-01-28

3.  The Combination of Galanin (1-15) and Escitalopram in Rats Suggests a New Strategy for Alcohol Use Disorder Comorbidity with Depression.

Authors:  Noelia Cantero-García; Antonio Flores-Burgess; David Ladrón de Guevara-Miranda; Antonia Serrano; Laura García-Durán; Araceli Puigcerver; Kjell Fuxe; José Ángel Narváez; Luis Javier Santín; Zaida Díaz-Cabiale; Carmelo Millón
Journal:  Biomedicines       Date:  2022-02-09

4.  The Cognitive-Enhancing Effects of Dendrobium nobile Lindl Extract in Sleep Deprivation-Induced Amnesic Mice.

Authors:  Ning Jiang; Yu-Jiao Li; Meng-di Wang; Hong Huang; Shanguang Chen; Yinghui Li; Lina Qu; Fengzhong Wang; Xinmin Liu; Qiong Wang
Journal:  Front Psychiatry       Date:  2022-01-19       Impact factor: 4.157

5.  Galanin (1-15) Enhances the Behavioral Effects of Fluoxetine in the Olfactory Bulbectomy Rat, Suggesting a New Augmentation Strategy in Depression.

Authors:  Antonio Flores-Burgess; Carmelo Millón; Belen Gago; Laura García-Durán; Noelia Cantero-García; Araceli Puigcerver; José Angel Narváez; Kjell Fuxe; Luis Santín; Zaida Díaz-Cabiale
Journal:  Int J Neuropsychopharmacol       Date:  2022-04-19       Impact factor: 5.678

Review 6.  The Galaninergic System: A Target for Cancer Treatment.

Authors:  Manuel Lisardo Sánchez; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2022-08-01       Impact factor: 6.575

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.